Drug duo aims to stop deadly skin Cancer's return
NCT ID NCT04666272
Summary
This study is observing whether a combination of two drugs, dabrafenib and trametinib, can help prevent melanoma skin cancer from returning in Chinese patients who have had it surgically removed. The treatment is given for one year to patients whose cancer has a specific genetic change (BRAF V600 mutation) and was at an advanced stage. Researchers will track if and when the cancer comes back, and monitor the safety of the drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Fuzhou, Fujian, 350014, China
-
Novartis Investigative Site
Zhengzhou, Henan, 410100, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Changsha, Hunan, 410013, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210008, China
-
Novartis Investigative Site
Kunming, Yunnan, 650106, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310022, China
-
Novartis Investigative Site
Beijing, 100036, China
Conditions
Explore the condition pages connected to this study.